Effect of erlotinib on proliferation and differentiation of JAK2V617F-positive cells in vitro.
- Author:
Yuan-Yuan REN
1
;
Ling-Yan ZHANG
;
Ying LI
Author Information
1. Department of Hematology, Shandong University, Jinan, China.
- Publication Type:Journal Article
- MeSH:
Cell Differentiation;
drug effects;
Cell Proliferation;
drug effects;
Cells, Cultured;
Erlotinib Hydrochloride;
Hematopoietic Stem Cells;
cytology;
Humans;
Janus Kinase 2;
metabolism;
Polycythemia Vera;
pathology;
Quinazolines;
pharmacology
- From:
Journal of Experimental Hematology
2012;20(2):368-371
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to investigate the effect of erlotinib on proliferation and differentiation of JAK2V617F-positive cells in vitro, and to provide experimental evidence of erlotinib for potential target therapy in polycythemia vera. Colony forming assays were used to detect the effect of erlotinib on differentiation of hematopoietic progenitor cells from bone marrow of polycythemia vera patients, and MTT method was used to measure the proliferation of HEL cell line containing the JAK2V617F mutation. The results showed that erlotinib 5 µmol/L inhibited the differentiation of JAK2V617F-positive hematopoietic progenitor cells into hematopoietic colonies in vitro, while it had almost no effect on normal hematopoietic progenitor cells from the patients. Erlotinib had inhibitory effect on the proliferation of HEL cell line in a dose dependent manner. The IC(50) was 4.1 µmol/L. It is concluded that erlotinib can inhibit proliferation and differentiation of JAK2V617F-positive cells to a certain extent in vitro.
